Stocks Health care NKTR
NASDAQ · Health careNektar Therapeutics (NKTR)
Nektar Therapeutics brought in $54.6M of revenue over the twelve months to June 30, 2026, down 27.2% from a year earlier. It posted a net loss of $157.1M. In fiscal 2025 capital spending exceeded operating cash flow by $208.7M. At June 30, 2026 it held $39.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Nektar Therapeutics does
Nektar Therapeutics is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NKTR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $55.2M | -$164.1M | -$9.73 | -$208.7M |
| 2024 | $98.4M | -$119M | -$8.68 | -$177.2M |
| 2023 | $90.1M | -$276.1M | -$21.70 | -$193.5M |
| 2022 | $92.1M | -$368.2M | -$29.48 | -$309.7M |
| 2021 | $101.9M | -$523.8M | -$42.80 | -$427.6M |
| 2020 | $152.9M | -$444.4M | -$37.26 | -$320.5M |
Latest SEC filings
What Nektar Therapeutics has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026Other event 8-K
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 5, 2026
Questions about NKTR
What does Nektar Therapeutics do?
Nektar Therapeutics is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NKTR.
Is Nektar Therapeutics profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $157.1M on revenue of $54.6M.
How much revenue does Nektar Therapeutics make?
Over the twelve months to June 30, 2026 Nektar Therapeutics reported revenue of $54.6M. That is 27.2% less than a year earlier.
When did Nektar Therapeutics last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 25, 2026.
Similar companies
Follow NKTR
Get an email when Nektar Therapeutics files with the SEC: results, executive changes, material agreements and annual reports.
Follow NKTR: get an email when it filesWhere the numbers come from
Financial figures are the values Nektar Therapeutics tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.